Table 3 Outcomes of the β-blockers and non-β-blocker therapy groups
From: Association between β-blocker use and mortality in critically ill patients: a nested cohort study
Categorical Variables | ||||||
Variable | β-blocker N = 89 | Non β-blocker N = 434 | P value | Risk | ||
aOR | 95% CI | P value | ||||
ICU Mortality, (n%) | 18 (20.2) | 62 (14.3) | 0.16 | 1.56 | 0.83–2.9 | 0.16 |
Hospital Mortality, (n%) | 34 (38.2) | 121 (27.9) | 0.05 | 1.09 | 0.65, 1.83 | 0.73 |
180-day mortality, (n%) | 19 (23.0) | 69 (17.5) | 0.25 | 0.73 | 0.38–1.38 | 0.33 |
Sepsis, (n%) | 30 (33.7) | 173 (39.9) | 0.27 | 1.20 | 0.71–2.02 | 0.49 |
Severe Sepsis, (n%) | 23 (25.8) | 102 (23.5) | 0.63 | 1.68 | 0.95–2.97 | 0.08 |
Continuous Variables | ||||||
Parameter estimate | 95% CI | P value | ||||
Mechanical ventilation duration (days), mean ± SD | 10.5 ± 13.3 | 8.7 ± 8.7 | 0.11 | 2.66 | 0.34–4.99 | 0.17 |
ICU LOS (days), mean ± SD | 11.3 ± 14.0 | 10.0 ± 8.9 | 0.23 | 1.99 | −0.43-4.41 | 0.22 |
Hospital LOS (days), mean ± SD | 59.5 ± 101.9 | 55.0 ± 75.7 | 0.63 | 7.95 | −11.68-27.58 | 0.34 |